Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1- 42 in Alzheimer disease

Archives of Neurology

Volumn 57, Issue 1, 2000, Pages 100-105

  Mehta, Pankaj D ^a,d   Pirttilä, Tuula ^c   Mehta, Sangita P ^a   Sersen, Eugene A ^a   Aisen, Paul S ^b   Wisniewski, Henryk M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; FAMILIAL DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL;

EID: 0033975837     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.1.100     Document Type: Article

References (36)

1. Wisniewski HM, Wegiel J. The neuropathology of Alzheimer's disease. Neuroimaging Clin N Am. 1995;5:45-57.
2. Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994;53:438-447.
3. Selkoe D. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci. 1994;17:489-517.
4. Mehta PD, Kim KS, Wisniewski HM. ELISA as a laboratory test to aid the diagnosis of Alzheimer's disease. Techniques Diagn Pathol. 1991;2:99-112.
5. Hass C, Scholossmacher MG, Hung A-Y, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322-326.
6. Gravina SA, Libin H, Eckman CB, et al. Amyloid β protein (Aβ) in Alzheimer's disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms of Aβ40 and Aβ42(43). J Biol Chem. 1995;270:7013-7016.
7. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ42/43 and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42/43. Neuron. 1994;13:45-53.
8. Younkin SG, Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann Neurol. 1995;37:287-288.
9. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643-648.
10. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997;148: 41-45.
11. Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF Tau, Aβ1-40 and Aβ-42 (43) as a biochemical marker of Alzheimer's disease. J Neurol Sci. 1998;158:134-140.
12. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937-945.
13. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
14. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid β protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 1996;151:65-68.
15. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
16. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of appolipoprotein E allele ∈4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
17. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoproiein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649-9653.
18. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allele variation and receptor interactions. Neuron. 1993;11: 575-580.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
20. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 1990;31:545-548.
21. Potempska A, Mack K, Mehta PD, et al. Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides. Amyloid. 1999;6:14-21.
22. Mehta PD, Dalton AJ, Mehta SP, et al. Increased plasma amyloid β protein 1-42 levels in Down syndrome. Neurosci Lett. 1998;241:13-16.
23. Lehtimäki T, Pirttilä T, Mehta PD, Wisniewski HM, Frey H, Nikkari T. Apolipoprotein E (ApoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet. 1995; 95:39-42.
24. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med. 1995;333:1242-1247.
25. Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J Biol Chem. 1995;270:7563-7567.
26. Zlokovic BV. Cerebrovascular transport of Alzheimer's amyloid β and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 1996;59:1483-1497.
27. Stern RA, Trojanowski JQ, Lee VM-Y, et al. Antibodies to the β-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. FEBS Lett. 1990;264:43-47.
28. Pardridge WM, Vinters HV, Miller BL, Tourtellotte WW, Eisenberg JB, Yang J. High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin G. Biochem Biophys Res Commun. 1987;145:241-248.
29. Pirttilä T, Kim KS, Mehta PD, Frey H, Wisniewski HM. Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci. 1994;127:90-95.
30. Ishii K, Tamaoka A, Mizusawa H, et al. Aβ1-40 but not Aβ1-42 levels in cortex correlate with apolipoprotein E ∈4 allele dosage in sporadic Alzheimer's disease. Brain Res. 1997;748:250-252.
31. Samuels SC, Silverman JM, Marin DB, et al. CSF beta-amyloid, cognition, and ApoE genotype in Alzheimer's disease. Neurology. 1999;52:547-551.
32. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
33. Samuel W, Terry RD, DeTeresa R, Butters N, Masliah E. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol. 1994; 51:772-778.
34. Tamaoka A, Sawamura N, Odaka A, et al. Amyloid β protein 1-42/43 (Aβ1-42/ 43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res. 1995;679:151-156.
35. Hulstaert F, Blenow K, Ivanoiu, A, et al. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF. Neurology. 1999;52:1555-1562.
36. Southwick PC, Yamagata S, Echols CL, et al. Assessment of amyloid β protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem. 1996;66:259-265.